Sustained high R&D spend
R&D costs jumped ~INR 70 crore in Q2 due to phase III biosimilar trials; management expects elevated spend for at least four more quarters.
medium · management_commentary
Aurobindo Pharma Limited — Q2 FY25
Aurobindo Pharma delivered a steady Q2 FY25 with revenue of INR 7,796 crore (+8% YoY) and EBITDA margin of 20.1%, despite higher R&D costs and penicillin G ramp-up losses.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Freight cost volatility from Red Sea disruptions
Higher freight costs (~INR 30 crore impact) due to Red Sea issues; management expects normalization but uncertainty remains.
medium · management_commentaryUnit 3 injectable supply chain recovery timeline
Injectable sales declined 11% YoY due to voluntary production slowdown at Unit 3; full recovery expected only by Q4, with FDA reinspection likely in FY26 Q3.
high · analyst_questionBiosimilar omalizumab recruitment delays
Phase III recruitment for omalizumab is 3-4 months behind schedule, potentially pushing back filing timelines.
low · management_commentary